首页> 美国卫生研究院文献>Journal of Cancer >Multiple Primary Malignant Tumors - A Clinical Analysis of 15321 Patients with Malignancies at a Single Center in China
【2h】

Multiple Primary Malignant Tumors - A Clinical Analysis of 15321 Patients with Malignancies at a Single Center in China

机译:多发原发性恶性肿瘤-中国单一中心15321例恶性肿瘤患者的临床分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background: Multiple primary malignant tumors (MPMTs) are defined as two or more histologically distinct malignancies in one individual, standard treatments for MPMTs are not well established, we aimed to clinical analyze the factors influence the treatment efficacy of MPMTs.>Methods: This study retrospectively analyzed 15,321 malignant tumor patients at the Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, China, between March 2006 and June 2016. The survival analysis was performed with SPSS version 22.0 (SPSS Inc., Chicago, IL, USA) with Kaplan-Meier methodology.>Results: The prevalence of MPMTs in our study was 1.09% (167/15321), with a male to female ratio of 2.34:1. Specifically, 98 patients harbored synchronous MPMTs, and 69 patients harbored metachronous MPMTs. The most common cancer pairs were digestive-digestive tumor (43 patients, 25.75%), digestive-lung cancer (32 patients, 19.16%), and head & neck-digestive tumor (11 patients, 6.59%). Among patients with synchronous and metachronous first primary cancers, 65.86% received surgery. 33.33% (27/81) of the patients with synchronous MPMTs received simultaneous resection. Of the 69 patients with metachronous MPMTs, 31.88% (22/69) were treated with surgery alone, 62.32% (43/69) received chemotherapy and/or radiotherapy for the first primary tumor, and 44.93% (31/69) received surgery for the other primary tumor. 98.20% (164/167) of patients with MPMTs were effectively followed up, the overall 2- and 5-year survival rates were 54.3% and 31.4%, respectively, with a median survival time of 28.0 months.>Conclusions: The early diagnosis of rare MPMTs should not be neglected in patients not only when treated for a primary malignancy but also during long-term follow-up. Effective treatment for MPMTs may yield promising curative effect and warrants further investigation.
机译:>背景:多个原发性恶性肿瘤(MPMT)被定义为一个人中两个或多个在组织学上不同的恶性肿瘤,MPMT的标准治疗方法尚不完善,我们旨在通过临床分析影响该药治疗效果的因素MPMTs。>方法:该研究回顾性分析了2006年3月至2016年6月在中国浙江大学医学院附属邵逸夫医院的15321例恶性肿瘤患者。采用SPSS进行生存分析。版本22.0(SPSS Inc.,美国伊利诺伊州芝加哥)采用Kaplan-Meier方法。>结果:本研究中MPMT的患病率为1.09%(167/15321),男女比例为2.34:1。具体而言,有98例患者携带同步MPMT,69例患者携带异时MPMT。最常见的癌症对是消化消化肿瘤(43例,占25.75%),消化道肺癌(32例,占19.16%)和头颈部消化道肿瘤(11例,占6.59%)。在患有同步和异时初发癌的患者中,有65.86%接受了手术。 33.33%(27/81)的同步性MPMT患者接受了同时切除。在69例异时性MPMT患者中,仅接受手术治疗的占31.88%(22/69),对于第一个原发性肿瘤接受化疗和/或放疗的患者为62.32%(43/69),而接受手术的患者为44.93%(31/69)用于其他原发肿瘤。有效随访了98.20%(164/167)的MPMT患者,其2年和5年总生存率分别为54.3%和31.4%,中位生存时间为28.0个月。>结论:< / strong>罕见的MPMT的早期诊断不仅在原发性恶性肿瘤治疗中,而且在长期随访中也不应忽略。有效治疗MPMT可能产生有希望的疗效,值得进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号